Conflict of Interest
EMD
Che-Kai Tsao: Exelixis, Eisai, Sanofi, Bristol Myers Squibb (consulting/advisory), Exelixis (research funding); Tomi Jun: Sema4 (employment); Yixuan Gong: Sema4 (employment); Matthew D. Galsky: Bristol Myers Squibb, Novartis, Dendreon, AstraZeneca, Merck, Genentech (research funding), Bristol Myers Squibb, Merck, Genentech, and AstraZeneca, Pfizer, EMD Serono, Seattle Genetics, Janssen, Numab, Dragonfly, GlaxoSmithKline, Basilea, UroGen, Alligator Biosciences, Curis, Rappta Therapeutics (consulting and scientific advisory board); William K. Oh: Sanofi, Janssen, AstraZeneca, Bayer, Huya Bioscience, TeneoBio, Advanced Accelerator Applications, Foundry, GlaxoSmithKline, Merck, Pfizer (consulting/advisory). Bobby C. Liaw and Sonia Seng indicated no financial relationships.